Tracleer Related Published Studies
Well-designed clinical trials related to Tracleer (Bosentan)
Bosentan in pulmonary hypertension associated with fibrotic idiopathic
interstitial pneumonia. [2014]
BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. [2011.07.01]
Rationale and design of a trial on the role of bosentan in Fontan patients: improvement of exercise capacity? [2011.07]
Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension. [2011.06]
Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. [2011.01]
Acute effect of sildenafil is maintained in pulmonary arterial hypertension patients chronically treated with bosentan. [2011]
Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. [2010.09.28]
Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis. [2010.07]
Lack of a pharmacokinetic interaction between oral treprostinil and bosentan in healthy adult volunteers. [2010.07]
Greater functional ETB receptor antagonism with bosentan than sitaxsentan in healthy men. [2010.06]
Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial. [2010.05]
Exercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan: results of the ASSET studies. [2010.05]
A randomized, double-blind, placebo-controlled study of high-dose bosentan in patients with stage IV metastatic melanoma receiving first-line dacarbazine chemotherapy. [2010.03.30]
Effect of the dual endothelin receptor antagonist bosentan on Raynaud's phenomenon secondary to systemic sclerosis: a double-blind prospective, randomized, placebo-controlled pilot study. [2010.03]
Quality of life and dyspnoea in patients treated with bosentan for idiopathic pulmonary fibrosis (BUILD-1). [2010.01]
Bosentan as a bridge to pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension. [2010.01]
Mutual pharmacokinetic interactions between bosentan and lopinavir/ritonavir in healthy participants. [2010]
Greater functional ETB receptor antagonism with bosentan than sitaxsentan in
healthy men. [2010]
Effect of the dual endothelin receptor antagonist bosentan on Raynaud's
phenomenon secondary to systemic sclerosis: a double-blind prospective,
randomized, placebo-controlled pilot study. [2010]
Bosentan decreases pulmonary vascular resistance and improves exercise capacity in acute hypoxia. [2009.05]
Prophylactic bosentan does not improve exercise capacity or lower pulmonary artery systolic pressure at high altitude. [2009.02.28]
Effect of bosentan upon pulmonary hypertension in chronic obstructive pulmonary disease. [2009.02]
Bosentan in the treatment of pulmonary arterial hypertension with the focus on the mildly symptomatic patient. [2009]
Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. [2008.12.16]
Prophylactic bosentan does not improve exercise capacity or lower pulmonary artery systolic pressure at high altitude. [2008.10.11]
Longer-term bosentan therapy improves functional capacity in Eisenmenger syndrome: results of the BREATHE-5 open-label extension study. [2008.06.23]
Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. [2008.06.21]
A randomized, controlled trial of bosentan in severe COPD. [2008.04.30]
BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. [2008.01.01]
A Randomized Placebo-Controlled Trial of Bosentan in Patients with Idiopathic Pulmonary Fibrosis. [2007.09.27]
Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis. [2007.06]
Inhibitory and inductive effects of rifampin on the pharmacokinetics of bosentan in healthy subjects. [2007.03]
Sitaxsentan treatment for patients with pulmonary arterial hypertension discontinuing bosentan. [2007.01]
Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. [2006.12.01]
An open-label, multicentre pilot study of bosentan in pulmonary arterial hypertension related to congenital heart disease. [2006.11]
Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. [2006.07.04]
Pharmacokinetic interaction between bosentan and the oral contraceptives norethisterone and ethinyl estradiol. [2006.03]
Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension. [2005.10]
Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension. [2005.10]
The endothelin-1 receptor antagonist bosentan protects against ischaemia/reperfusion-induced endothelial dysfunction in humans. [2005.04]
Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study. [2005.02]
Survival with first-line bosentan in patients with primary pulmonary hypertension. [2005.02]
Comparative investigation of the pharmacokinetics of bosentan in Caucasian and Japanese healthy subjects. [2005.01]
Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. [2004.12]
Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. [2004.09]
Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension. [2003.04.16]
Investigation of the mutual pharmacokinetic interactions between bosentan, a dual endothelin receptor antagonist, and simvastatin. [2003]
Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure? [2002.10]
Single- and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazole. [2002.06]
In vivo and in vitro studies exploring the pharmacokinetic interaction between bosentan, a dual endothelin receptor antagonist, and glyburide. [2002.04]
Bosentan therapy for pulmonary arterial hypertension. [2002.03.21]
Influence of food intake and formulation on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist. [2002.03]
Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. [2001.10.06]
Hemodynamic effects of Bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension. [2000.07.25]
Renal hemodynamics and pharmacokinetics of bosentan with and without cyclosporine A. [2000.01]
Effect of the endothelin-receptor antagonist bosentan on the pharmacokinetics and pharmacodynamics of warfarin. [1999.08]
Multiple-dose pharmacokinetics, safety, and tolerability of bosentan, an endothelin receptor antagonist, in healthy male volunteers. [1999.07]
The effect of bosentan on the pharmacokinetics of digoxin in healthy male subjects. [1999.06]
Protection against aspirin-induced human gastric mucosal injury by bosentan, a new endothelin-1 receptor antagonist. [1999.05]
Hemodynamic and coronary effects of the endothelin antagonist bosentan in patients with coronary artery disease. [1998.11.24]
The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators. [1998.03.19]
Acute and short-term effects of the nonpeptide endothelin-1 receptor antagonist bosentan in humans. [1997.01]
Endothelin antagonist bosentan blocks neurogenic inflammation, but is not effective in aborting migraine attacks. [1996.10]
Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects. [1996.08]
Well-designed clinical trials possibly related to Tracleer (Bosentan)
Endothelin antagonism and uric acid levels in pulmonary arterial hypertension:
clinical associations. [2014]
Race and sex differences in response to endothelin receptor antagonists for
pulmonary arterial hypertension. [2012]
[Treatment of pulmonary fibrosis : New substances and new interventions.] [2011.11.19]
Long-term effects of inhaled treprostinil in patients with pulmonary arterial
hypertension: the Treprostinil Sodium Inhalation Used in the Management of
Pulmonary Arterial Hypertension (TRIUMPH) study open-label extension. [2011]
Atrial septal defects versus ventricular septal defects in BREATHE-5, a placebo-controlled study of pulmonary arterial hypertension related to Eisenmenger's syndrome: a subgroup analysis. [2010.10.29]
Development and validity testing of an IPF-specific version of the St George's Respiratory Questionnaire. [2010.10]
Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. [2010.05.04]
Tadalafil: in pulmonary arterial hypertension. [2010.03.05]
Endothelin receptors blockade blunts hypoxia-induced increase in PAP in humans. [2010.03]
The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference. [2010.02]
The effects of sitaxentan on sildenafil pharmacokinetics and pharmacodynamics in healthy subjects. [2010.01]
Addition of inhaled treprostinil to oral therapy for pulmonary arterial
hypertension: a randomized controlled clinical trial. [2010]
Tadalafil: in pulmonary arterial hypertension. [2010]
The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and
minimum important difference. [2010]
No clinically relevant pharmacokinetic and safety interactions of ambrisentan in combination with tadalafil in healthy volunteers. [2009.12]
Insights into the mechanisms and mediators of the effects of air pollution exposure on blood pressure and vascular function in healthy humans. [2009.09]
Atrial septal defects versus ventricular septal defects in BREATHE-5, a placebo-controlled study of pulmonary arterial hypertension related to Eisenmenger's syndrome: A subgroup analysis. [2009.05.20]
Endothelin receptor antagonist therapy in congenital heart disease with shunt-associated pulmonary arterial hypertension: a qualitative systematic review. [2009.03]
Oral therapies for the treatment of pulmonary arterial hypertension: a population-based cost-minimization analysis. [2009]
Selective endothelin A-receptor blockade attenuates coronary microvascular dysfunction after coronary stenting in patients with type 2 diabetes. [2009]
Management of Pulmonary Arterial Hypertension Associated with Congenital Systemic-to-Pulmonary Shunts and Eisenmenger's Syndrome. [2008]
Treprostinil for pulmonary hypertension. [2008]
Evidence-based pharmacologic management of pulmonary arterial hypertension. [2007.10]
Does endothelin play a role in chemoreception during acute hypoxia in normal men? [2007.05]
Sitaxsentan for treatment of pulmonary hypertension. [2007.01]
Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. [2006.12]
Role of endothelin-1 in exposure to high altitude: Acute Mountain Sickness and Endothelin-1 (ACME-1) study. [2006.09.26]
Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. [2006.05.16]
Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study. [2005.06.01]
[Emerging Therapies for the Treatment of Pulmonary Arterial Hypertension.] [2005.06]
Combined inhibition of angiotensin II and endothelin suppresses the brain natriuretic peptide response to developing heart failure. [2004.06]
Regulation of aldosterone secretion in patients with chronic congestive heart failure by endothelins. [2000.04.15]
Update of REACH-1 and MERIT-HF clinical trials in heart failure. Cardio.net Editorial Team. [1999.06]
Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. [1998.11.24]
Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. [1995.09.16]
Other research related to Tracleer (Bosentan)
Impact of bosentan on exercise capacity in adults after the Fontan procedure: a
randomized controlled trial. [2013]
Long-term effect of bosentan therapy on cardiac function and symptomatic benefits
in adult patients with Eisenmenger syndrome. [2012]
|